摘要
ObjectiveAlthough the application of immunotherapy in gastric cancer has achieved satisfactory clinical effects, many patients have no response. The aim of this retrospective study is to investigate the predictive ability of the prognostic nutrition index (PNI) to the prognosis of patients with gastric cancer who received immune checkpoint inhibitors (ICIs). Materials and methodsParticipants were 146 gastric cancer patients with ICIs (PD-1/PD-L1 inhibitors) or chemotherapy. All patients were divided into a low PNI group and a high PNI group based on the cut-off evaluated by the receiver operating characteristic (ROC) curve. We contrasted the difference in progression-free survival (PFS) and overall survival (OS) in two groups while calculating the prognosis factors for PFS and OS by univariate and multivariate analyses. Moreover, the nomogram based on the results of the multivariate analysis was constructed to estimate the 1- and 3-year survival probabilities. ResultsThere were 41 (28.1%) cases in the low PNI group and 105 (71.9%) cases in the high PNI group. The median survival time for PFS in the low PNI group and high PNI group was 12.30 months vs. 33.07 months, and 18.57 months vs. not reached in the two groups for OS. Patients in low PNI group were associated with shorter PFS and OS in all patients [Hazard ratio (HR) = 1.913, p = 0.013 and HR = 2.332, p = 0.001]. Additionally, in subgroup analysis, low PNI group cases also had poorer PFS and OS, especially in patients with ICIs. In addition, the multivariate analysis found that carbohydrate antigen 724 (CA724) and TNM stage were independent prognostic factors for PFS. At the same time, indirect bilirubin (IDBIL), CA724, PNI, and TNM stage were independent prognostic factors for OS. ConclusionPrognostic nutrition index was an accurate inflammatory and nutritional marker, which could predict the prognosis of patients with gastric cancer who received ICIs. PNI could be used as a biomarker for ICIs to identify patients with gastric cancer who might be sensitive to ICIs.
学科与关键词
- Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) OutcomesChen, Li; Sun, Hao; Zhao, Ruihu; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*Frontiers in Pharmacology, 2022, 13: 836958.被引 16
- The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 InhibitorsChen, Li; Zhao, Ruihu; Sun, Hao; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*Frontiers in Pharmacology, 2022, 13: 833584.被引 4
- Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes (vol 13, 836958, 2022)Chen, Li; Sun, Hao; Zhao, Ruihu; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Song, Hongjiang*; Li, Xingrui*Frontiers in Pharmacology, 2022, 13: 1079635.
